AstraZeneca’s (LON:AZN) SGLT2 inhibitor Farxiga (dapagliflozin) led to a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular death or worsening heart failure in the DELIVER Phase 3 study.  First FDA approved in 2014 as a type 2 diabetes treatment, Farxiga has scored approvals related to heart failure and chronic kidney…

Entresto (sacubitril-valsartan) from Novartis is FDA indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure. Entresto remains the only FDA-approved option for patients with a variety of heart failure symptoms. A recent pilot study shows that the drug may also benefit patients with heart failure…

The Galien Foundation has revealed its latest nominees for the 2021 Prix Galien USA Award highlighting innovations in biotechnology, pharmaceutical agents, medical technology and digital health products. Entrants to the competition must have received FDA approval within the past five years and demonstrate exceptional therapeutic potential. The Galien Foundation does not use financial data to…

Novartis (NYSE:NVS) has agreed to acquire Cadent Therapeutics, a privately owned neuroscience company based in Cambridge, Mass. Novartis plans to spend $210 million upfront with another $560 million in milestone payments.  The acquisition would give Novartis two neuroscience drugs in clinical development — one for schizophrenia and another for movement disorders. The transaction also includes a…